Impact News +++ SPAC King Chamath Palihapitiya Hails Rare Earth Play MP Materials As Stock Nears $100: One Of The Deals That... (Benzinga) +++ MP MATERIALS Aktie +3,17%

DENALI THERAPEUTICS Aktie

>Aktienkurs

12.67 EUR -2.2% (Tradegate)

Ask: 12.93 EUR / 463 Stück

Bid: 12.675 EUR / 472 Stück

Tagesumsatz: 2541 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: 0%

1 Monat: +7,5%

3 Monate: +6,1%

6 Monate: +17,0%

1 Jahr: -44,3%

laufendes Jahr: -33,4%

>DENALI THERAPEUTICS Aktie

Name:

DENALI THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US24823R1059 / A2H9G8

Symbol/ Ticker:

4DN (Frankfurt) / DNLI (NASDAQ)

Kürzel:

FRA:4DN, ETR:4DN, 4DN:GR, NASDAQ:DNLI

Index:

Webseite:

https://denalitherapeutic..

Profil:

Denali Therapeutics Inc. is a biotechnology compan..
>Volltext..

Marktkapitalisierung:

1934.4 Mio. EUR

Unternehmenswert:

1214.17 Mio. EUR

Umsatz:

EBITDA:

-451.49 Mio. EUR

Nettogewinn:

-412.34 Mio. EUR

Gewinn je Aktie:

-2.42 EUR

Schulden:

40.08 Mio. EUR

Liquide Mittel:

121.55 Mio. EUR

Operativer Cashflow:

-300.94 Mio. EUR

Bargeldquote:

9.87

Umsatzwachstum:

-100%

Gewinnwachstum:

-3.79%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

DENALI THERAPEUTICS, DENALI THERAPEUTIC

Letzte Datenerhebung:

14.10.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 146.21 Mio. St.

Frei handelbar: 89.48%

Leerverk. Aktien: 9.68%

Rückkaufquote: -0.63%

Mitarbeiter: 422

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 105.22%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 2.21

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -35.9%

Eigenkaprendite: -39.69%

>Peer Group

Es sind 599 Aktien bekannt.

>Chart & Kurs - NASDAQ

>Alle News

13.10.25 - 22:33	Denali Therapeutics gets FDA review extension for tividenofusp alfa (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.10.25 - 22:03

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire EN)

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. The Prescription Drug User Fee Act (PDUFA) target date has been extended from January 5, 2026, to April 5, 2026....

10.09.25 - 19:00	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
	Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

15.08.25 - 07:01	Insiderhandel: COFO and Secretary verkauft Aktien von Denali Therapeutics im Wert von 39884 USD (Insiderkauf)
	Schuth, Alexander O. - Vorstand - Tag der Transaktion: 2025-08-12...

15.08.25 - 07:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Denali Therapeutics im Wert von 11800 USD (Insiderkauf)
	Ho, Carole - Vorstand - Tag der Transaktion: 2025-08-13...

12.08.25 - 16:00	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in ′26 (Zacks)
	Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals....

11.08.25 - 22:42	Denali Therapeutics GAAP EPS of -$0.72 in-line (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.08.25 - 22:06	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire EN)
	SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights....

17.07.25 - 14:18

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company′s Board of Directors (GlobeNewswire EN)

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing....

12.07.25 - 00:01	Insiderhandel: President and CEO verkauft Aktien von Denali Therapeutics im Wert von 7429230 USD (Insiderkauf)
	Watts, Ryan J. - Vorstand - Tag der Transaktion: 2025-07-09...

06.05.25 - 22:03	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire EN)
	SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights....

02.04.25 - 22:18	What Happened To Denali Therapeutics Stock Wednesday? (Benzinga)
	Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the treatment of Hunter syndrome. read more...

02.04.25 - 14:03

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program (GlobeNewswire EN)

SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has been received by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA). Denali continues to have regular, collaborative, and productive engagement with CDER and is aligned with CDER on the content of the BLA data package, including the use of cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate endpoint to support an accelerated approval, as well as the full approval conversion path. Denali expects to complete the BLA submission in the first half of May 2025 and continues to prepare for a potential commercial launch in the U.S. in late 2025 or early 2026....

28.02.25 - 23:15	Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.02.25 - 22:03	Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire EN)
	SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights....

06.02.25 - 17:45

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa (GlobeNewswire EN)

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These data, along with recent Breakthrough Therapy designation, further support the company's plan to submit a biologics license application (BLA) in early 2025 for accelerated approval and deliver this potential treatment to the Hunter syndrome community in late 2025 or early 2026. The Phase 1/2 results are being presented this week at the 21st Annual WORLDSymposium™ conference in San Diego, California....

13.01.25 - 18:39	Denali Therapeutics sees cash runway into 2028 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.01.25 - 04:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Denali Therapeutics im Wert von 247796 USD (Insiderkauf)
	Ho, Carole - Vorstand - Tag der Transaktion: 2025-01-06...

10.01.25 - 04:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Denali Therapeutics im Wert von 69485 USD (Insiderkauf)
	Krognes, Steve E. - Aufsichtsrat - Tag der Transaktion: 2025-01-07...

10.01.25 - 04:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Denali Therapeutics im Wert von 60495 USD (Insiderkauf)
	Ho, Carole - Vorstand - Tag der Transaktion: 2025-01-07...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn sich zwei Herzen scheiden, die sich dereinst geliebt, das ist ein großes Leiden, wie′s größ′res nimmer gibt. - Emanuel Geibel

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram